Rituximab News and Research

RSS

Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.

Light-Activated Macrophages Show Increased Appetite for Cancer Cells

The body has a veritable army constantly on guard to keep us safe from microscopic threats from infections to cancer.

13 Aug 2024

Key discovery could prevent treatment failure in people with severe hemophilia A

Recently, researchers achieved a crucial discovery that could mitigate and eliminate immune responses causing treatment failure in people with hemophilia A.

20 Apr 2021

New analysis technique could pave way for major breakthroughs in immunotherapy

In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphatic leukaemia.

14 Dec 2020

New radioimmunotherapy effectively reverses resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

9 Oct 2020